Specifically, FAM162A transcript levels were upregulated in several mouse disease models including transverse aortic constriction-induced (TAC) heart failure, myocardial infarction, and hypertrophic cardiomyopathy (Fig. 9a). Here, FAM162A is linked to hypertrophic cardiomyopathy.